Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CF - Cystic Fibrosis Clear all
Completed Phase 1Phase 2 Interventional

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

NCT06159725
View directory record Official record
Conditions
Persistent Infection, Cystic Fibrosis
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis

NCT03391414
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hypertonic bicarbonate, sodium chloride
Drug
Lead sponsor
Joseph Pilewski
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational

Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients

NCT04994301
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lung T1 MRI
Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multilevel Models of Therapeutic Response in the Lungs

NCT02947126
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hypertonic Saline, Isotonic Saline, Indium-DTPA, Technetium Sulfur Colloid
Drug
Lead sponsor
Tim Corcoran
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Jul 22, 2026, 2:04 AM EDT
Active, not recruiting No phase listed Observational

Colorectal Cancer Screening in Cystic Fibrosis

NCT05362344
View directory record Official record
Conditions
Cystic Fibrosis, Colorectal Cancer, Adenoma
Interventions
Stool tests
Procedure
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2008 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Comparison of Airway Clearance Efficacy of Two High Frequency Chest Wall Oscillation (HFCWO) Devices in Cystic Fibrosis

NCT00308958
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
High frequency chest wall oscillator
Device
Lead sponsor
University of Minnesota
Other
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 22, 2026, 2:04 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
View directory record Official record
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of NeoPlex4 Assay and NeoPlex System

NCT01488721
View directory record Official record
Conditions
Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
1 Day to 7 Days
Enrollment
7,462 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Albany, New York • Nashville, Tennessee • Taylorsville, Utah
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational

G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2)

NCT01521338
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Steven M Rowe
Other
Eligibility
6 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Impact of Support Groups for Patients With Non-Cystic Fibrosis Bronchiectasis

NCT06164470
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Support Group
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

NCT03525574
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
52
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls

NCT01331980
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Peripheral quantitative computed tomography (pQCT), Dual X-ray absorptiometry (DXA)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 12 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

NCT06861413
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 22, 2026, 2:04 AM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

NCT02823470
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA, activated smart device, de-activated smart device
Drug · Device
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Hartford, Connecticut • Washington D.C., District of Columbia • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Early Phase 1 Interventional

Gender Disparity and Hormones in Cystic Fibrosis

NCT02036879
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
Loestrin (norethindrone acetate and ethinyl estradiol)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Jul 22, 2026, 2:04 AM EDT
Terminated Phase 1 Interventional Results available

Growth Hormone Therapy for Wasting in Cystic Fibrosis

NCT00803179
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nutropin AQ
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805
View directory record Official record
Conditions
Pulmonary/Respiratory Diseases
Interventions
Placebo, AZD5634
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

NCT01858519
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 99 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
47
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03746483
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
MS1819, Porcine PERT
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational

Determinants of Early Cystic Fibrosis Lung Disease

NCT03579173
View directory record Official record
Conditions
Cystic Fibrosis in Children
Interventions
Infant PFT, Lung Clearance Index, Passive tidal breathing
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
1 Month to 5 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Jul 22, 2026, 2:04 AM EDT
Recruiting Phase 2 Interventional

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Interventions
Dulaglutide 0.75Mg/0.5Ml Inj Pen
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational

Measurement of Beta Cell Death in Individuals With Cystic Fibrosis

NCT03713437
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Measurement of differentially methylated insulin DNA
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 21 Years
Enrollment
40 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilocarpine Microneedles for Sweat Induction (PMN-SI)

NCT04732195
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pilocarpine microneedle patch, Pilocarpine Iontophoresis
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Jul 22, 2026, 2:04 AM EDT